الصفحة الرئيسية>>Signaling Pathways>> Tyrosine Kinase>> Src>>Src I1

Src I1

رقم الكتالوجGC16957

Src I1 هو مثبط ثنائي قوي ومنافس لـ ATP وانتقائي ثنائي الموقع Src tyrosine kinase بقيم IC50 تبلغ 44 نانومتر لـ Src و 88 نانومتر لـ Lck.

Products are for research use only. Not for human use. We do not sell to patients.

Src I1 التركيب الكيميائي

Cas No.: 179248-59-0

الحجم السعر المخزون الكميّة
10mM (in 1mL DMSO)
40٫00
متوفر
2mg
35٫00
متوفر
5mg
49٫00
متوفر
10mg
67٫00
متوفر
25mg
154٫00
متوفر
50mg
277٫00
متوفر

Tel:(909) 407-4943 Email: sales@glpbio.com

مراجعات العميل

بناء على آراء العملاء.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Protocol Chemical Properties Product Documents Related Products

Src Inhibitor 1 is a potent and selective dual site Src tyrosine kinase inhibitor with IC50 values of 44 nM for Src and 88nM for Lck.

Src-I1 is competitive with both ATP and peptide binding sites of the kinase. The IC50 values are 44 and 88 nM for Src and Lck, respectively[1]. Src-I1, is found to be a potent inhibitor of Src (IC50=0.18 μM), but also inhibited other Src family members, such as Lck, Csk and Yes with similar potency to Src, and RIP2 (IC50=0.026 μM) with even greater potency. In addition, it inhibited CHK2 with similar potency to Src, and Aurora B with slightly lower potency[2].

References:
[1]. Tian G, et al. Structural determinants for potent, selective dual site inhibition of human pp60c-src by 4-anilinoquinazolines. Biochemistry. 2001 Jun 19;40(24):7084-91.
[2]. Bain J, et al. The selectivity of protein kinase inhibitors: a further update. Biochem J. 2007 Dec 15;408(3):297-315.

مراجعات

Review for Src I1

Average Rating: 5 ★★★★★ (Based on Reviews and 26 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Src I1

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.